Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial growth, and generate cost efficiencies. The pharma industry has recently seen a flurry of significant M&As with more surely to follow. This white paper highlights the importance that M&As will have on the future performance of pharma companies. M&As will be required to achieve strategic objectives by augmenting and/or complementing existing company R&D pipelines as the risks and costs of developing new innovative medicines increase over time. The challenges for pharma companies are making the right targeting decisions for M&As and tactically ensuring such deals achieve strategic goals.
The objectives of this white paper are designed to help pharma executives in making critical M&A decisions by addressing five key questions:
- What is (will be) driving current and future M&A deals?
- Do M&As improve R&D productivity? If so, how? If not, why not?
- Do M&As increase shareholder value? If so, how? If not, why not?
- Are there any therapy classes that are more likely targets for increased M&A activity?
- What kinds of analyses should companies conduct when considering M&As in order to increase the probability of such deals improving R&D productivity and increasing shareholder value?
Complete the brief form to download the white paper.
Contact us at insights@axtria.com with any questions.
